-
公开(公告)号：KR1020120049634A
公开(公告)日：2012-05-17
申请号：KR1020100110992
申请日：2010-11-09
Applicant: (주)아모레퍼시픽
IPC: G01N33/15 , G01N33/483
Abstract: PURPOSE: A method for evaluating efficiency of UV protector is provided to measure cell apoptosis rate and to accurately protect UV ray. CONSTITUTION: A method for evaluating efficiency of UV protector comprises: a step of applying an UV protector onto UV permeable material; a step of irradiating UV onto the upper portion of the UV permeable material; and a step of measuring cell death of skin cells. The UV permeable material is a quartz plate or band pass filter. The skin cells include keratinocytes, fibroblasts, or melanocytes. The cell death includes apoptosis and necrosis.
Abstract translation: 目的：提供一种评估紫外线保护剂效率的方法，以测量细胞凋亡率并准确保护紫外线。 构成：用于评价UV保护剂效率的方法包括：将UV保护剂涂布在UV透过性材料上的步骤; 将UV照射到UV可渗透材料的上部的步骤; 以及测量皮肤细胞的细胞死亡的步骤。 UV透光材料是石英板或带通滤光片。 皮肤细胞包括角质形成细胞，成纤维细胞或黑素细胞。 细胞死亡包括凋亡和坏死。
-
公开(公告)号：KR101114006B1
公开(公告)日：2012-02-21
申请号：KR1020080052041
申请日：2008-06-03
Applicant: (주)아모레퍼시픽
Abstract: 본 발명은 피부 미용 및 성형용 조성물에 관한 것으로, 보다 상세하게는 백화사설초 추출물을 유효성분으로 함유하여 사람 중간엽줄기세포를 지방세포로 분화하는 것을 촉진시킴으로써 지방세포를 생성하여 피부의 볼륨과 탄력을 부여하는 미용 또는 성형 조성물에 관한 것이다.
백화사설초 * 중간엽 줄기세포 분화 * 지방세포생성-
公开(公告)号：KR1020100103670A
公开(公告)日：2010-09-27
申请号：KR1020107017553
申请日：2008-12-03
Applicant: (주)아모레퍼시픽
CPC classification number: A61K31/15
Abstract: PURPOSE: A slimming cosmetic composition containing 2-cyclopentene-1-one oxime derivative is provided to promote lipid lysis in adipocytes(3T3-L1) and to reduce body fat. CONSTITUTION: A slimming cosmetic composition contains 2-cyclopentene-1-one oxime derivatives compound of chemical formula 1 or pharmaceutically acceptable salt as an active ingredient. The cosmetic composition induces decrease of neutral fat by promoting lipid lysis. The cosmetic composition is used in the form of emulsion, lotion, cream, gel, oil, spray, ointment, powder, compact, pack cleanser, shampoo, rinse, patch, or pad.
Abstract translation: 目的：提供含有2-环戊烯-1-酮肟衍生物的减肥美容组合物，以促进脂肪细胞（3T3-L1）中的脂质溶解，并减少体脂肪。 构成：减肥化妆品组合物含有化学式1的2-环戊烯-1-酮肟衍生物化合物或其药学上可接受的盐作为活性成分。 化妆品组合物通过促进脂质溶解诱导中性脂肪的减少。 化妆品组合物以乳液，洗剂，霜剂，凝胶，油，喷雾剂，软膏剂，粉剂，紧凑型包装清洁剂，洗发剂，漂洗剂，补片或垫片的形式使用。
-
公开(公告)号：KR100964433B1
公开(公告)日：2010-06-16
申请号：KR1020080110377
申请日：2008-11-07
Applicant: (주)아모레퍼시픽
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/158
Abstract: 본 발명은 피부 기능 향상 물질을 스크리닝(screening)하는 방법으로서, (a) 후보 물질을 피부 세포에 처리하는 단계; (b) MAP17(Membrane-Associated Protein 17kD) 유전자의 상대적 발현량 변화를 검출하는 단계; 및 (c) 상기 유전자의 발현량 변화를 유도하는 후보 물질을 피부 기능 향상 물질로 선택하는 단계를 포함한다.
즉, 본 발명은 MAP17(Membrane-Associated Protein 17kD) 유전자를 표지인자로 하여 MAP17 유전자의 발현량 변화를 통해 피부 기능 향상 물질을 검색하는 신규한 스크리닝 방법으로서, 이를 통해 피부 장벽 기능 향상, 피부 보습 유지, 피부 노화 방지 또는 피부 트러블 완화에 유용한 피부 기능 향상 물질을 효율적으로 스크리닝할 수 있다.
MAP17(Membrane-Associated Protein 17kD), 스크리닝-
115.发明公开(-)카테친, (-)에피카테친 갈레이트 및 (-)갈로카테친을 함유하는 피부 미용, 성형용, 및 당뇨병 예방 또는 치료용 조성물 无效用于改善糖尿病的组合物和用于促进人间质干细胞分化成含有（ - ）卡培喹的（ - ）环磷酰胺，（ - ）GALLOCATECHIN
公开(公告)号：KR1020100025045A
公开(公告)日：2010-03-09
申请号：KR1020080083645
申请日：2008-08-27
Applicant: (주)아모레퍼시픽
IPC: A61K31/353 , A61P3/10
Abstract: PURPOSE: A medicinal composition for preventing or treating diabetes and plastic surgery is provided to promote adipocyte differentiation and to enhance volume and elasticity of skin. CONSTITUTION: A medicinal composition for promoting differentiation of adipocytes contains (-)catechin, (-)epicatechin gallate, or (-)gallocatechin as an active ingredient. Adipocyte is human bone marrow mesenchymal stem cell. The (-)catechin, (-)epicatechin gallate, or (-)gallocatechin is isolated from green tea. A medicinal composition for treating and preventing type II diabetes and diabetes complication contains the (-)catechin, (-)epicatechin gallate, or (-)gallocatechin.
Abstract translation: 目的：提供用于预防或治疗糖尿病和整形手术的药物组合物，以促进脂肪细胞分化并增强皮肤的体积和弹性。 构成：用于促进脂肪细胞分化的药用组合物含有（ - ）儿茶素，（ - ）表儿茶素没食子酸酯或（ - ）儿茶素素作为活性成分。 脂肪细胞是人骨髓间充质干细胞。 （ - ）儿茶素，（ - ）表儿茶素没食子酸酯或（ - ）儿茶素可与绿茶分离。 用于治疗和预防II型糖尿病和糖尿病并发症的药物组合物含有（ - ）儿茶素，（ - ）表儿茶素没食子酸酯或（ - ）儿茶素。
-
Patent Agency Ranking
公开(公告)号：KR1020100000392A
公开(公告)日：2010-01-06
申请号：KR1020080059873
申请日：2008-06-24
Applicant: (주)아모레퍼시픽
CPC classification number: A61K8/498 , A61K31/352 , A61Q19/00
Abstract: PURPOSE: A method and composition for promoting skin regeneration using icariside II is provided to promote proliferation of transient amplifying cells of epidermis base and promote skin regeneration. CONSTITUTION: An icariside II of chemical formula 1 promotes proliferation of skin cells in skin cells. The skin cell is transient amplifying cells(TA cells). A composition for promoting skin regeneration contains the icariside II as an active ingredient. The content of the active ingredient is 0.001-10 weight% based on total weight. The composition regenerates epidermis by promoting proliferation of the TA cells. The composition increases the number of TA cells which express CD71 protein (Cluster of Differentiation 71 Protein) and α6 integrin. The composition increases the expression of CD200(Cluster of Differentiation 200).
Abstract translation: 目的：提供使用艾司替丁II促进皮肤再生的方法和组合物，以促进表皮碱基瞬时扩增细胞的增殖并促进皮肤再生。 构成：化学式1的阿奇瑞德II促进皮肤细胞中皮肤细胞的增殖。 皮肤细胞是瞬时扩增细胞（TA细胞）。 用于促进皮肤再生的组合物含有作为活性成分的阿魏酸二酯。 活性成分的含量为0.001-10重量％。 该组合物通过促进TA细胞的增殖而再生表皮。 该组合物增加表达CD71蛋白（分化蛋白簇71）和α6整联蛋白的TA细胞的数量。 该组合物增加CD200（分化群集200）的表达。
-
117.发明公开아라키도닐 도파민을 함유하는 지방세포 분화 억제 및지방세포 내의 지질체 수준 감소용 약학 조성물 有权含有ARACHIDONYL DOPAMINE的药物组合物，用于抑制ADIPOCYTE中ADIPOCYTE的分化和降低水平的降低水平
公开(公告)号：KR1020090119159A
公开(公告)日：2009-11-19
申请号：KR1020080045032
申请日：2008-05-15
Applicant: (주)아모레퍼시픽
IPC: A61K31/202 , A61P3/04
CPC classification number: A61K31/202 , A61K9/0019 , A61K9/08 , A61K9/20 , A61K9/48
Abstract: PURPOSE: A pharmaceutical composition for suppressing adipocyte differentiation and reducing lipid droplet is provided to prevent or treat obesity or lipoma. CONSTITUTION: A pharmaceutical composition of adipocyte differentiation contains arachidonyl dopamine. The pharmaceutical composition prevents adipose tissue enlargement-related disease. The adipose tissue enlargement-related disease is obesity or lipoma. The differentiation of adipocyte is from mesenchymal stem cell to adipocyte. The mesenchymal stem cell is human bone marrow mesenchymal stem cell. A formulation of oral administration is used in the form of pill, powder, suspension, emulsion, syrup, and granule.
Abstract translation: 目的：提供抑制脂肪细胞分化和降低脂滴的药物组合物，以预防或治疗肥胖或脂肪瘤。 构成：脂肪细胞分化的药物组合物含有花生四烯多巴胺。 该药物组合物防止脂肪组织扩大相关疾病。 脂肪组织增生相关疾病是肥胖或脂肪瘤。 脂肪细胞的分化是从间充质干细胞到脂肪细胞。 间充质干细胞是人骨髓间充质干细胞。 口服给药的制剂以丸剂，粉剂，悬浮液，乳剂，糖浆剂和颗粒剂的形式使用。
-
118.发明公开ＰＧＣ1-알파 프로모터를 발현하는 형질감염 세포주 및이를 이용한 ＰＧＣ1-알파 프로모터 부위의 활성을측정하는 방법 无效表达PGC1-ALPHA促进剂的转染细胞系和测量PGC1-ALPHA促进剂位点的活性的方法
公开(公告)号：KR1020090057834A
公开(公告)日：2009-06-08
申请号：KR1020070124591
申请日：2007-12-03
Applicant: (주)아모레퍼시픽
Abstract: A method for measuring the activity of transfection cell line and PGC1-alpha promoter is provided to search a material inducing the expression of PGC1-alpha and easily measuring the activity of PGC1-alpha promoter site. A transfection cell line which expresses a PGC1-alpha is transfected by a vector containing human PGC1-alpha promoter, antibiotic resistance gene, and reporter gene. The antibiotic resistance gene has neomycin and kanamycin. The reporter gene is luciferase gene. The vector is plasmid. A method for measuring the activity of PGC1-alpha promoter site comprises: a step of treating a PGC1-alpha promoter regulation material in the transfected cell line; and a step of measuring the activity of reporter gene.
Abstract translation: 提供了一种测量转染细胞系和PGC1-α启动子的活性的方法，以搜索诱导PGC1-α表达的物质，并容易测定PGC1-α启动子位点的活性。 通过含有人PGC1-α启动子，抗生素抗性基因和报道基因的载体转染表达PGC1-α的转染细胞系。 抗生素抗性基因具有新霉素和卡那霉素。 报告基因为萤光素酶基因。 载体是质粒。 测量PGC1-α启动子位点活性的方法包括：处理转染细胞系中PGC1-α启动子调节物质的步骤; 以及测定报道基因的活性的步骤。
-
公开(公告)号：KR1020080051239A
公开(公告)日：2008-06-11
申请号：KR1020060121960
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/166 , A61K31/045 , A61P3/04
Abstract: A pharmaceutical composition comprising compounds capable of increasing expressions of isocitrate dehydrogenase 3alpha(IDH3alpha) and carnitine palmitoyl transferase 1A(CPT1A) by increasing activity of their promoters is provided to reduce synthesis of fatty acid and promote oxidation of fatty acid, so that the composition is useful for treating and preventing lipid metabolism-related diseases. A pharmaceutical composition for treating and preventing lipid metabolism-related diseases comprises compounds represented by the formula(1) in which R1 is adamantly group or phenyl group substituted by H, OH or C1-C5 alkyl, and R2 is CONH or NHCO, and further comprises pharmaceutically acceptable carriers, excipients or diluents selected from lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, crystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
Abstract translation: 提供了包含通过提高其启动子的活性而能够增加异柠檬酸脱氢酶3α（IDH3α）和肉碱棕榈酰转移酶1A（CPT1A）的表达的化合物的药物组合物，用于减少脂肪酸的合成并促进脂肪酸的氧化，使得组合物 用于治疗和预防脂质代谢相关疾病。 用于治疗和预防脂质代谢相关疾病的药物组合物包括由式（1）表示的化合物，其中R1是金刚烷基或被H，OH或C1-C5烷基取代的苯基，R2是CONH或NHCO， 包括药学上可接受的载体，赋形剂或稀释剂，其选自乳糖，葡萄糖，蔗糖，山梨糖醇，甘露糖醇，木糖醇，赤藓糖醇，麦芽糖醇，淀粉，阿拉伯胶，藻酸盐，明胶，磷酸钙，硅酸钙，纤维素，甲基纤维素，结晶纤维素，聚乙烯吡咯烷酮 ，水，羟基苯甲酸甲酯，羟基苯甲酸丙酯，滑石，硬脂酸镁和矿物油。
-
公开(公告)号：KR1020080035378A
公开(公告)日：2008-04-23
申请号：KR1020060102010
申请日：2006-10-19
Applicant: (주)아모레퍼시픽 , 재단법인서울대학교산학협력재단
IPC: A61K31/047 , A61P3/04 , A61P3/06 , A61P3/10
Abstract: A composition for inhibiting the activity of glucose-6-phosphate dehydrogenase is provided to inhibit production of NADPH(nicotinamide adenine dinucleotide phosphate) and fat biosynthesis, so that the composition is useful for prevention and treatment of fat metabolism disorders including obesity, hyperlipidemia and diabetes. A composition for inhibiting the activity of glucose-6-phosphate dehydrogenase comprises the compounds represented by the formula(1) selected from epigallocatechin gallate, gallocatechin gallate, epicatechin gallate, catechin gallate, octyl gallate and lauryl gallate, wherein R^1 is H or OH, R^2 is a structural formula 1 or 2, R^3 is C3-C20 alkyl, X is a structural formula 3 or 4, and R^4 is H or a structural formula 5; and the compounds represented by the formula(1) is quercetin or myricetin.
Abstract translation: 提供用于抑制葡萄糖-6-磷酸脱氢酶活性的组合物以抑制NADPH（烟酰胺腺嘌呤二核苷酸磷酸酯）的产生和脂肪生物合成，使得该组合物可用于预防和治疗脂肪代谢障碍，包括肥胖症，高脂血症和糖尿病 。 用于抑制葡萄糖-6-磷酸脱氢酶活性的组合物包括选自表没食子儿茶素没食子酸酯，没食子儿茶素没食子酸酯，表儿茶素没食子酸酯，儿茶素没食子酸酯，没食子酸辛酯和没食子酸月桂酯的式（1）表示的化合物，其中R 1是H或 OH，R 2是结构式1或2，R 3是C 3 -C 20烷基，X是结构式3或4，R 4是H或结构式5; 由式（1）表示的化合物是槲皮素或杨梅素。
-
-
-
-
-
-
-
-
-
Search Results
155
records
(took 0.04 seconds)
